Rafael Pharmaceuticals said Thursday that its experimental treatment for pancreatic cancer failed to prolong the lives of patients in a large clinical trial.
A separate study of the same Rafael drug, called devimistat, involving patients with a type of leukemia, was also stopped early after an interim analysis concluded the drug was not working, the company said.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
